<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">J Toxicol</journal-id><journal-id journal-id-type="publisher-id">JT</journal-id><journal-title-group><journal-title>Journal of Toxicology</journal-title></journal-title-group><issn pub-type="ppub">1687-8191</issn><issn pub-type="epub">1687-8205</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23431291</article-id><article-id pub-id-type="pmc">3575612</article-id><article-id pub-id-type="doi">10.1155/2013/463595</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Analysis of Safety from a Human Clinical Trial with Pterostilbene</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Riche</surname><given-names>Daniel M.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>McEwen</surname><given-names>Corey L.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Riche</surname><given-names>Krista D.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sherman</surname><given-names>Justin J.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wofford</surname><given-names>Marion R.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Deschamp</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Griswold</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA</aff><aff id="I2"><sup>2</sup>Department of Medicine, The University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA</aff><aff id="I3"><sup>3</sup>Department of Pharmacy, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA</aff><aff id="I4"><sup>4</sup>Department of Pharmacy, St. Dominic Hospital, 969 Lakeland Drive, Jackson, MS 39216, USA</aff><author-notes><corresp id="cor1">*Daniel M. Riche: <email>driche@umc.edu</email></corresp><fn fn-type="other"><p>Academic Editor: Lucio Guido Costa</p></fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>4</day><month>2</month><year>2013</year></pub-date><volume>2013</volume><elocation-id>463595</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>5</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Daniel M. Riche et al.</copyright-statement><copyright-year>2013</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="3926" xml_f="3927" txt_i="11" txt_f="12">
</offsets><italic><offsets xml_i="3935" xml_f="3945" txt_i="12" txt_f="22">Objectives</offsets></italic><offsets xml_i="3954" xml_f="4062" txt_i="22" txt_f="130">. The purpose of this trial was to evaluate the safety of long-term pterostilbene administration in humans. </offsets><italic><offsets xml_i="4070" xml_f="4081" txt_i="130" txt_f="141">Methodology</offsets></italic><offsets xml_i="4090" xml_f="4745" txt_i="141" txt_f="796">. The trial was a prospective, randomized, double-blind placebo-controlled intervention trial enrolling patients with hypercholesterolemia (defined as a baseline total cholesterol ≥200 mg/dL and/or baseline low-density lipoprotein cholesterol ≥100 mg/dL). Eighty subjects were divided equally into one of four groups: (1) pterostilbene 125 mg twice daily, (2) pterostilbene 50 mg twice daily, (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily, and (4) matching placebo twice daily for 6–8 weeks. Safety markers included biochemical and subjective measures. Linear mixed models were used to estimate primary safety measure treatment effects. </offsets><italic><offsets xml_i="4753" xml_f="4760" txt_i="796" txt_f="803">Results</offsets></italic><offsets xml_i="4769" xml_f="5103" txt_i="803" txt_f="1137">. The majority of patients completed the trial (91.3%). The average age was 54 years. The majority of patients were females (71%) and Caucasians (70%). There were no adverse drug reactions (ADRs) on hepatic, renal, or glucose markers based on biochemical analysis. There were no statistically significant self-reported or major ADRs. </offsets><italic><offsets xml_i="5111" xml_f="5121" txt_i="1137" txt_f="1147">Conclusion</offsets></italic><offsets xml_i="5130" xml_f="5199" txt_i="1147" txt_f="1216">. Pterostilbene is generally safe for use in humans up to 250 mg/day.</offsets></p></abstract></article-meta></front><body><sec id="sec1"><title><offsets xml_i="5265" xml_f="5280" txt_i="1224" txt_f="1239">1. Introduction</offsets></title><p><offsets xml_i="5291" xml_f="5479" txt_i="1240" txt_f="1428">Pterostilbene is a phenol that is chemically related to resveratrol, a possible contributor to the “French Paradox” which associates red wine consumption and lower coronary heart disease [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="5510" xml_f="5511" txt_i="1428" txt_f="1429">1</offsets></xref><offsets xml_i="5518" xml_f="5520" txt_i="1429" txt_f="1431">, </offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="5551" xml_f="5552" txt_i="1431" txt_f="1432">2</offsets></xref><offsets xml_i="5559" xml_f="6069" txt_i="1432" txt_f="1942">]. Naturally found in blueberries and grapes, pterostilbene is a phytoalexin, a class of compounds naturally synthesized by plants during pathogen infection. The primary structural difference between pterostilbene and resveratrol is that pterostilbene contains two methoxy groups and one hydroxyl group while resveratrol has three hydroxyl groups. The two methoxy groups cause pterostilbene to be more lipophilic, which increases oral absorption and gives pterostilbene a higher potential for cellular uptake [</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="6100" xml_f="6101" txt_i="1942" txt_f="1943">3</offsets></xref><offsets xml_i="6108" xml_f="6254" txt_i="1943" txt_f="2089">]. Pterostilbene has a longer half-life (105 minutes versus 14 minutes) and higher oral bioavailability (80% versus 20%) compared to resveratrol [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="6285" xml_f="6286" txt_i="2089" txt_f="2090">4</offsets></xref><offsets xml_i="6293" xml_f="6294" txt_i="2090" txt_f="2091">–</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="6325" xml_f="6326" txt_i="2091" txt_f="2092">7</offsets></xref><offsets xml_i="6333" xml_f="6449" txt_i="2092" txt_f="2208">]. Pterostilbene also has low total body clearance and subsequent Vss which suggests extensive tissue distribution [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="6480" xml_f="6481" txt_i="2208" txt_f="2209">4</offsets></xref><offsets xml_i="6488" xml_f="6490" txt_i="2209" txt_f="2211">].</offsets></p><p><offsets xml_i="6497" xml_f="6739" txt_i="2212" txt_f="2454">There has been extensive animal research examining both the safety and efficacy of pterostilbene. Animal studies have demonstrated efficacy in cardiometabolics (e.g., cholesterol and blood glucose), as well as cancer and cognition mediators [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="6770" xml_f="6771" txt_i="2454" txt_f="2455">8</offsets></xref><offsets xml_i="6778" xml_f="6779" txt_i="2455" txt_f="2456">–</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="6811" xml_f="6813" txt_i="2456" txt_f="2458">10</offsets></xref><offsets xml_i="6820" xml_f="6823" txt_i="2458" txt_f="2461">]. </offsets></p><p><offsets xml_i="6830" xml_f="7149" txt_i="2462" txt_f="2781">Substances that are generally recognized as safe (GRAS) are exempt from premarket Food and Drug Administration (FDA) review and may be intentionally added to food. The criteria for GRAS status are described in sections 201(s) and 409 of the Food Additives Amendment to the Federal Food, Drug, and Cosmetic Act in 1958 [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="7181" xml_f="7183" txt_i="2781" txt_f="2783">11</offsets></xref><offsets xml_i="7190" xml_f="7338" txt_i="2783" txt_f="2931">]. After 1958, any food substance must be scientifically evaluated by experts and deemed safe for human consumption to attain the GRAS recognition [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="7370" xml_f="7372" txt_i="2931" txt_f="2933">11</offsets></xref><offsets xml_i="7379" xml_f="7381" txt_i="2933" txt_f="2935">].</offsets></p><p><offsets xml_i="7388" xml_f="7468" txt_i="2936" txt_f="3016">A short-term, open-label trial conducted in 13 healthy volunteers evaluated the </offsets><italic><offsets xml_i="7476" xml_f="7483" txt_i="3016" txt_f="3023">in vivo</offsets></italic><offsets xml_i="7492" xml_f="7535" txt_i="3023" txt_f="3066"> activity of a pterostilbene-rich extract (</offsets><italic><offsets xml_i="7543" xml_f="7564" txt_i="3066" txt_f="3087">Pterocarpus marsupium</offsets></italic><offsets xml_i="7573" xml_f="7751" txt_i="3087" txt_f="3265">). Safety parameters were evaluated through blood drawn. No changes from baseline parameters were demonstrated. There were also no observed adverse events of major body systems [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="7783" xml_f="7785" txt_i="3265" txt_f="3267">12</offsets></xref><offsets xml_i="7792" xml_f="7969" txt_i="3267" txt_f="3444">]. This healthy volunteer trial did not examine synthesized or pure pterostilbene with a blinded control and did not investigate long-term safety in a target patient population.</offsets></p><p><offsets xml_i="7976" xml_f="8076" txt_i="3445" txt_f="3545">Our trial is the first controlled trial performed in humans evaluating the safety of pterostilbene. </offsets></p></sec><sec id="sec2"><title><offsets xml_i="8108" xml_f="8122" txt_i="3547" txt_f="3561">2. Methodology</offsets></title><p><offsets xml_i="8133" xml_f="8990" txt_i="3562" txt_f="4419">This trial was a prospective, randomized, double-blind placebo-controlled intervention trial. This trial was approved by the University of Mississippi Medical Center Institutional Review Board. The target population was patients with hypercholesterolemia, defined as a baseline total cholesterol ≥200 mg/dL and/or, baseline low-density lipoprotein cholesterol ≥100 mg/dL. Patients were included if they were ≥18 years of age and on either no cholesterol therapy or cholesterol medication at a stable dose for at least 2 months prior to baseline laboratory. Patients were excluded if they had significant hepatic, renal, or gastrointestinal tract disease, were receiving thiazolidinediones or fibric acid derivatives, had current overt cardiovascular disease, were women of reproductive potential not receiving birth control, or were pregnant/nursing women. </offsets></p><p><offsets xml_i="8997" xml_f="9374" txt_i="4420" txt_f="4797">The trial planned for an enrollment of 80. Subjects were divided equally into one of four groups: pterostilbene 50 mg twice daily (low dose), pterostilbene 125 mg twice daily (high dose), pterostilbene 50 mg/grape extract 100 mg twice daily (low dose + grape extract), or matching placebo twice daily for 6–8 weeks. Ciprofibrate is a peroxisome proliferator-activated receptor-</offsets><italic><offsets xml_i="9382" xml_f="9383" txt_i="4797" txt_f="4798">α</offsets></italic><offsets xml_i="9392" xml_f="9399" txt_i="4798" txt_f="4805"> (PPAR-</offsets><italic><offsets xml_i="9407" xml_f="9408" txt_i="4805" txt_f="4806">α</offsets></italic><offsets xml_i="9417" xml_f="9428" txt_i="4806" txt_f="4817">) agonist [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="9459" xml_f="9460" txt_i="4817" txt_f="4818">8</offsets></xref><offsets xml_i="9467" xml_f="9514" txt_i="4818" txt_f="4865">]. Pterostilbene has demonstrated similar PPAR-</offsets><italic><offsets xml_i="9522" xml_f="9523" txt_i="4865" txt_f="4866">α</offsets></italic><offsets xml_i="9532" xml_f="9604" txt_i="4866" txt_f="4938"> activation at approximately equimolar concentrations in animal models [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="9635" xml_f="9636" txt_i="4938" txt_f="4939">4</offsets></xref><offsets xml_i="9643" xml_f="10035" txt_i="4939" txt_f="5331">]. Since a standard human dose of ciprofibrate is 100 mg/day, this dose was selected for the lowest effective pterostilbene dose in monotherapy and combination. The higher daily dose was evaluated to assess for potential dose-related efficacy or adverse effect. All patients received identical counseling on lifestyle intervention and compliance with currently prescribed medication regimens.</offsets></p><p><offsets xml_i="10042" xml_f="10291" txt_i="5332" txt_f="5581">The manufacturer of the pterostilbene and placebo products was deemed in compliance by the FDA current good manufacturing practices prior to the initiation of this trial. The process of pterostilbene synthesis for this trial is described elsewhere [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="10323" xml_f="10325" txt_i="5581" txt_f="5583">13</offsets></xref><offsets xml_i="10332" xml_f="10334" txt_i="5583" txt_f="5585">].</offsets></p><p><offsets xml_i="10341" xml_f="10999" txt_i="5586" txt_f="6244">The safety markers included biochemical and subjective measures collected at two visits (baseline and final). Donated blood was analyzed for all biochemical measures at the same laboratory values. Primary safety measures included Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), serum creatinine, and blood glucose. Other safety markers include blood electrolytes and symptomatic subjective adverse drug reactions (ADRs) collected during patient interviews at baseline and final visits. Blood pressure, cholesterol, and weight were collected and reported separately as efficacy endpoints. Pill counts were utilized to assess for compliance. </offsets></p><p><offsets xml_i="11006" xml_f="11398" txt_i="6245" txt_f="6637">Linear mixed models were used to estimate primary safety measure treatment effects in order to account for intra subject associations arising from the repeated measures before and after longitudinal design. The underlying missing-at-random architecture implicit in mixed models was assumed. Various models were fit to examine potential baseline effects including as appropriate the following:</offsets><list list-type="order"><list-item><p><offsets xml_i="11436" xml_f="11513" txt_i="6637" txt_f="6714">3-way interaction models of final outcome × treatment group × baseline value;</offsets></p></list-item><list-item><p><offsets xml_i="11543" xml_f="11632" txt_i="6715" txt_f="6804">2-way interaction models including all 2-way terms from (1) but excluding the 3-way term;</offsets></p></list-item><list-item><p><offsets xml_i="11662" xml_f="11743" txt_i="6805" txt_f="6886">models assuming baseline value affected change similarly across treatment groups;</offsets></p></list-item><list-item><p><offsets xml_i="11773" xml_f="11842" txt_i="6887" txt_f="6956">models assuming change in outcome were independent of baseline value.</offsets></p></list-item></list><offsets xml_i="11865" xml_f="11866" txt_i="6957" txt_f="6958">
</offsets></p><p><offsets xml_i="11873" xml_f="12139" txt_i="6959" txt_f="7225">Each model was examined in unadjusted and adjusted form (adjusting for age, gender and race). Final reported treatment effects were obtained from the simplest appropriate adjusted model for each outcome. For secondary measures compared to baseline and/or placebo, a </offsets><italic><offsets xml_i="12147" xml_f="12148" txt_i="7225" txt_f="7226">t</offsets></italic><offsets xml_i="12157" xml_f="12258" txt_i="7226" txt_f="7327">-test was performed for continuous data and a Fisher's exact test was performed for dichotomous data.</offsets></p></sec><sec id="sec3"><title><offsets xml_i="12290" xml_f="12300" txt_i="7329" txt_f="7339">3. Results</offsets></title><p><offsets xml_i="12311" xml_f="12348" txt_i="7340" txt_f="7377">Patient demographics are detailed in </offsets><xref ref-type="table" rid="tab1"><offsets xml_i="12382" xml_f="12389" txt_i="7377" txt_f="7384">Table 1</offsets></xref><offsets xml_i="12396" xml_f="12720" txt_i="7384" txt_f="7708">. Over 90% of patients who enrolled completed the trial with an average duration of 52 days. Over 80% of trial completers demonstrated 80% or higher compliance based on pill counts. The average age of all trial participants was 54 years. The majority of patients were females and Caucasians. Among the pterostilbene groups (</offsets><italic><offsets xml_i="12728" xml_f="12729" txt_i="7708" txt_f="7709">n</offsets></italic><offsets xml_i="12738" xml_f="12965" txt_i="7709" txt_f="7936"> = 60), 2 patients were lost to follow up and 2 patients withdrew from the trial. One withdrawal was due to a lost trial medication bottle and the other withdrawal was due to worsening of cholesterol from an outside laboratory.</offsets></p><p><offsets xml_i="12972" xml_f="13044" txt_i="7937" txt_f="8009">There was no biochemical ADRs on liver, kidney, or glucose markers (See </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="13076" xml_f="13084" txt_i="8009" txt_f="8017">Figure 1</offsets></xref><offsets xml_i="13091" xml_f="13173" txt_i="8017" txt_f="8099">). There were no statistically significant self-reported ADRs versus placebo (see </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="13207" xml_f="13214" txt_i="8099" txt_f="8106">Table 2</offsets></xref><offsets xml_i="13221" xml_f="13407" txt_i="8106" txt_f="8292">). There were no major ADRs (e.g., hospitalization, new-onset disease, infection, or death). There was a significant 3.6% reduction in bicarbonate in the high-dose group versus placebo (</offsets><italic><offsets xml_i="13415" xml_f="13416" txt_i="8292" txt_f="8293">P</offsets></italic><offsets xml_i="13425" xml_f="13577" txt_i="8293" txt_f="8445"> = 0.02) with a similar trend in both low-dose groups. The combination of grape extract and low-dose pterostilbene decreased BUN by 7.1% from baseline (</offsets><italic><offsets xml_i="13585" xml_f="13586" txt_i="8445" txt_f="8446">P</offsets></italic><offsets xml_i="13595" xml_f="13670" txt_i="8446" txt_f="8521"> = 0.01), but this reduction was not significant when compared to placebo (</offsets><italic><offsets xml_i="13678" xml_f="13679" txt_i="8521" txt_f="8522">P</offsets></italic><offsets xml_i="13688" xml_f="13761" txt_i="8522" txt_f="8595"> = 0.20). There were no other significant effects on electrolyte markers.</offsets></p><p><offsets xml_i="13768" xml_f="14014" txt_i="8596" txt_f="8842">Additionally, we performed a single-blinded quality assessment of 2 samples from 3 randomly selected bottles in each trial arm. The average amount of pterostilbene was 95% or higher of the listed active ingredient amount in all samples evaluated.</offsets></p></sec><sec id="sec4"><title><offsets xml_i="14046" xml_f="14059" txt_i="8844" txt_f="8857">4. Discussion</offsets></title><p><offsets xml_i="14070" xml_f="14326" txt_i="8858" txt_f="9114">This is the first well-designed comparison of pterostilbene in a dose-ranging controlled human trial. There appears to be no direct effect of pterostilbene on measures of hepatic or renal function. The proposed mechanism of action of pterostilbene is PPAR-</offsets><italic><offsets xml_i="14334" xml_f="14335" txt_i="9114" txt_f="9115">α</offsets></italic><offsets xml_i="14344" xml_f="14354" txt_i="9115" txt_f="9125"> agonism [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="14385" xml_f="14386" txt_i="9125" txt_f="9126">4</offsets></xref><offsets xml_i="14393" xml_f="14434" txt_i="9126" txt_f="9167">]. Currently available FDA-approved PPAR-</offsets><italic><offsets xml_i="14442" xml_f="14443" txt_i="9167" txt_f="9168">α</offsets></italic><offsets xml_i="14452" xml_f="14640" txt_i="9168" txt_f="9356"> agonists (e.g., fenofibrate or pioglitazone) have both renal and hepatic dose adjustments required. Fenofibrate has reported increases in serum creatinine from baseline by 12% as an ADR [</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="14672" xml_f="14674" txt_i="9356" txt_f="9358">14</offsets></xref><offsets xml_i="14681" xml_f="14905" txt_i="9358" txt_f="9582">]. Despite a high prevalence of a combination with statin, pterostilbene did not demonstrate any biochemical hepatic ADRs. There does not appear to be a need for such precautions with pterostilbene in doses up to 250 mg/day.</offsets></p><p><offsets xml_i="14912" xml_f="15336" txt_i="9583" txt_f="10007">No patients taking statins reported myopathy. Myopathy was reported in patients not taking statins in both low-dose groups on 3 occasions. The lack of myopathy in the high-dose group and in statin users decreases the likelihood of this ADR in relation to pterostilbene. Though a drug-drug interaction with statins appears unlikely, possible drug-drug interactions with other medication classes warrant further investigation.</offsets></p><p><offsets xml_i="15343" xml_f="15541" txt_i="10008" txt_f="10206">There is unlikely an association of pterostilbene with gastrointestinal ADR (with or without food) or itching as both reported ADRs occurred to a low extent in only the placebo and high dose groups.</offsets></p><p><offsets xml_i="15548" xml_f="15866" txt_i="10207" txt_f="10522">While &lt;20% of completers reported any dietary changes during the trial, increased appetite was reported in all three pterostilbene arms, but not placebo. Although detailed changes in weight will be reported separately, there was no overall trend towards an increase in body weight. Participants reporting this ADR (</offsets><italic><offsets xml_i="15874" xml_f="15875" txt_i="10522" txt_f="10523">n</offsets></italic><offsets xml_i="15884" xml_f="15975" txt_i="10523" txt_f="10614"> = 4) all gained weight (average 1.7 pounds). A possible mechanism is cross-selective PPAR-</offsets><italic><offsets xml_i="15983" xml_f="15984" txt_i="10614" txt_f="10615">γ</offsets></italic><offsets xml_i="15993" xml_f="16139" txt_i="10615" txt_f="10761"> activation of pterostilbene. This unique response in a small subgroup of patients warrants periodic weight monitoring and further investigation. </offsets></p><p><offsets xml_i="16146" xml_f="16489" txt_i="10762" txt_f="11105">The slight decrease in bicarbonate could indicate a minor acidic effect of pterostilbene in the blood. This is an expected outcome due to the general acidic nature of phenols, such as pterostilbene. This finding does indicate that the encapsulated method of delivery used in this trial appears to be sufficient for blood absorption in humans. </offsets></p><p><offsets xml_i="16496" xml_f="16823" txt_i="11106" txt_f="11433">Some limitations include a small trial population in one region of the United States over approximately 7 weeks. Also, the total daily dose was restricted to 250 mg and no patient reported overuse. While there are no obvious signs of toxicity at this maximum dose, the potential for toxicity cannot be excluded at higher doses.</offsets></p><p><offsets xml_i="16830" xml_f="17098" txt_i="11434" txt_f="11702">Neither complete blood count nor urinalysis was performed. Urine was collected for oxidative stress comparison only. Results of a previous short-term healthy volunteer trial demonstrated no baseline changes in blood count when evaluating a pterostilbene-rich extract [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="17129" xml_f="17130" txt_i="11702" txt_f="11703">8</offsets></xref><offsets xml_i="17137" xml_f="17266" txt_i="11703" txt_f="11832">]. The risk of hematological or urinary ADRs was not demonstrated in animal models or a common ADR with currently available PPAR-</offsets><italic><offsets xml_i="17274" xml_f="17275" txt_i="11832" txt_f="11833">α</offsets></italic><offsets xml_i="17284" xml_f="17568" txt_i="11833" txt_f="12117"> agonists. There was also no electrocardiogram (ECG) performed due to budgetary constraints. Additional evaluation of ECG monitoring is warranted considering that the target patient population is at-risk for cardiovascular disease and previous dietary supplements have demonstrated QT</offsets><sub><offsets xml_i="17573" xml_f="17574" txt_i="12117" txt_f="12118">c</offsets></sub><offsets xml_i="17580" xml_f="17611" txt_i="12118" txt_f="12149"> prolongation (i.e., Ephedra) [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="17643" xml_f="17645" txt_i="12149" txt_f="12151">15</offsets></xref><offsets xml_i="17652" xml_f="17655" txt_i="12151" txt_f="12154">]. </offsets></p><p><offsets xml_i="17662" xml_f="17897" txt_i="12155" txt_f="12390">In the United States, dietary supplements are not specifically monitored by a regulating body for assessment of quality. Unfortunately, some dietary supplements may contain varying and even absent amounts of listed active ingredients [</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="17929" xml_f="17931" txt_i="12390" txt_f="12392">16</offsets></xref><offsets xml_i="17938" xml_f="18009" txt_i="12392" txt_f="12463">]. In this trial, purity was confirmed in a blinded, randomized manner.</offsets></p></sec><sec id="sec5"><title><offsets xml_i="18041" xml_f="18054" txt_i="12465" txt_f="12478">5. Conclusion</offsets></title><p><offsets xml_i="18065" xml_f="18213" txt_i="12479" txt_f="12627">Pterostilbene is generally safe for use in humans at doses up to 250 mg per day. Pterostilbene is well-tolerated at a twice daily dosing frequency. </offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>This trial was supported by a grant through ChromaDex, Inc. ChromaDex, Inc. had no role in the collection or interpretation/analysis of data. The safety results were reported at the International Society of Antioxidants in Nutrition and Health (ISANH) 6th World Congress on Polyphenols Applications: Paris Polyphenols 2012. The authors would like to thank the pharmacy residents and students that participated in the data collection phase of this trial (Clinicaltrials.gov identifier NCT 01267227).</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrières</surname><given-names>J</given-names></name></person-group><article-title>The French paradox: lessons for other countries</article-title><source><italic>Heart</italic></source><year>2004</year><volume>90</volume><issue>1</issue><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="other">2-s2.0-0346059361</pub-id><pub-id pub-id-type="pmid">14676260</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>DK</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Ray</surname><given-names>PS</given-names></name><etal></etal></person-group><article-title>Cardioprotection of red wine: role of polyphenolic antioxidants</article-title><source><italic>Drugs under Experimental and Clinical Research</italic></source><year>1999</year><volume>25</volume><issue>2-3</issue><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="other">2-s2.0-0033034560</pub-id><pub-id pub-id-type="pmid">10370873</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HS</given-names></name><name><surname>Yue</surname><given-names>BD</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study</article-title><source><italic>Biomedical Chromatography</italic></source><year>2009</year><volume>23</volume><issue>12</issue><fpage>1308</fpage><lpage>1315</lpage><pub-id pub-id-type="other">2-s2.0-71649110385</pub-id><pub-id pub-id-type="pmid">19488981</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapetanovic</surname><given-names>IM</given-names></name><name><surname>Muzzio</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Thompson</surname><given-names>TN</given-names></name><name><surname>McCormick</surname><given-names>DL</given-names></name></person-group><article-title>Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats</article-title><source><italic>Cancer Chemotherapy and Pharmacology</italic></source><year>2011</year><volume>68</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">21116625</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asensi</surname><given-names>M</given-names></name><name><surname>Medina</surname><given-names>I</given-names></name><name><surname>Ortega</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Inhibition of cancer growth by resveratrol is related to its low bioavailability</article-title><source><italic>Free Radical Biology and Medicine</italic></source><year>2002</year><volume>33</volume><issue>3</issue><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="other">2-s2.0-0036667553</pub-id><pub-id pub-id-type="pmid">12126761</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remsberg</surname><given-names>CM</given-names></name><name><surname>Yáñez</surname><given-names>JA</given-names></name><name><surname>Ohgami</surname><given-names>Y</given-names></name><name><surname>Vega-Villa</surname><given-names>KR</given-names></name><name><surname>Rimando</surname><given-names>AM</given-names></name><name><surname>Davies</surname><given-names>NM</given-names></name></person-group><article-title>Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity</article-title><source><italic>Phytotherapy Research</italic></source><year>2008</year><volume>22</volume><issue>2</issue><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="other">2-s2.0-40549119870</pub-id><pub-id pub-id-type="pmid">17726731</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutakul</surname><given-names>W</given-names></name><name><surname>Sobers</surname><given-names>HS</given-names></name><name><surname>Qiu</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: a side-by-side comparison</article-title><source><italic>Journal of Agricultural and Food Chemistry</italic></source><year>2011</year><volume>59</volume><issue>20</issue><fpage>10964</fpage><lpage>10970</lpage><pub-id pub-id-type="pmid">21936500</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimando</surname><given-names>AM</given-names></name><name><surname>Nagmani</surname><given-names>R</given-names></name><name><surname>Feller</surname><given-names>DR</given-names></name><name><surname>Yokoyama</surname><given-names>W</given-names></name></person-group><article-title>Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor <italic>α</italic>-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters</article-title><source><italic>Journal of Agricultural and Food Chemistry</italic></source><year>2005</year><volume>53</volume><issue>9</issue><fpage>3403</fpage><lpage>3407</lpage><pub-id pub-id-type="other">2-s2.0-19944410516</pub-id><pub-id pub-id-type="pmid">15853379</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Agarwal</surname><given-names>AK</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol</article-title><source><italic>BMC Medical Genomics</italic></source><year>2008</year><volume>1, article 7</volume></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>CS</given-names></name><name><surname>Ma</surname><given-names>G</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Patny</surname><given-names>A</given-names></name><name><surname>Avery</surname><given-names>MA</given-names></name><name><surname>Rimando</surname><given-names>AM</given-names></name></person-group><article-title>Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPAR<italic>α</italic>
</article-title><source><italic>Bioorganic and Medicinal Chemistry</italic></source><year>2008</year><volume>16</volume><issue>7</issue><fpage>3800</fpage><lpage>3808</lpage><pub-id pub-id-type="other">2-s2.0-41649120931</pub-id><pub-id pub-id-type="pmid">18272370</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><collab>U.S. Department of Health and Human Services, Food and Drug Administration</collab><article-title>Guidance for industry: frequently asked questions about GRAS</article-title><year>2011</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/ucm061846.htm">http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/ucm061846.htm</ext-link></comment></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hougee</surname><given-names>S</given-names></name><name><surname>Faber</surname><given-names>J</given-names></name><name><surname>Sanders</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Selective COX-2 inhibition by a Pterocarpus marsupium extract characterized by pterostilbene, and its activity in healthy human volunteers</article-title><source><italic>Planta Medica</italic></source><year>2005</year><volume>71</volume><issue>5</issue><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="other">2-s2.0-20544470196</pub-id><pub-id pub-id-type="pmid">15931573</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Gottumukkala</surname><given-names>VS</given-names></name><name><surname>Masna</surname><given-names>M</given-names></name><name><surname>Hindupur</surname><given-names>RM</given-names></name><name><surname>Thatipally</surname><given-names>S</given-names></name></person-group><article-title>Inventors, aptuit laurus private limited, assignee. X.</article-title><comment>World patent WO, 2010/0101578 A2, 2009</comment></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsimihodimos</surname><given-names>V</given-names></name><name><surname>Kakafika</surname><given-names>A</given-names></name><name><surname>Elisaf</surname><given-names>M</given-names></name></person-group><article-title>Fibrate treatment can increase serum creatinine levels</article-title><source><italic>Nephrology Dialysis Transplantation</italic></source><year>2001</year><volume>16</volume><issue>6, article 1301</issue><pub-id pub-id-type="other">2-s2.0-0034970314</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>BF</given-names></name><name><surname>Karapanos</surname><given-names>AK</given-names></name><name><surname>Krudysz</surname><given-names>A</given-names></name><name><surname>Kluger</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>CI</given-names></name><name><surname>White</surname><given-names>CM</given-names></name></person-group><article-title>Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial</article-title><source><italic>Journal of the American Medical Association</italic></source><year>2004</year><volume>291</volume><issue>2</issue><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="other">2-s2.0-0345831912</pub-id><pub-id pub-id-type="pmid">14722148</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henyan</surname><given-names>NN</given-names></name><name><surname>Riche</surname><given-names>DM</given-names></name><name><surname>Pitcock</surname><given-names>JJ</given-names></name><name><surname>Strickland</surname><given-names>DC</given-names></name></person-group><article-title>Marked transaminase elevations and worsening glycemic control associated with counterfeit polyherbal use in a patient with diabetes</article-title><source><italic>Journal of Pharmacy Practice</italic></source><year>2009</year><volume>22</volume><issue>6</issue><fpage>600</fpage><lpage>605</lpage><pub-id pub-id-type="other">2-s2.0-77949400232</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Primary safety analysis.<italic> Interpretation:</italic> expected Changes in an Outcome (vertical axis) for any given level of baseline value (horizontal axis) across all four treatment groups. Adjusted for age, gender, and race.</p></caption><graphic xlink:href="JT2013-463595.001"></graphic></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Demographics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1">High dose</th><th align="center" rowspan="1" colspan="1">Low dose</th><th align="center" rowspan="1" colspan="1">Low dose + grape extract</th><th align="center" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">54</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (%) (M/F) </td><td align="center" rowspan="1" colspan="1">30/70</td><td align="center" rowspan="1" colspan="1">25/75</td><td align="center" rowspan="1" colspan="1">25/75</td><td align="center" rowspan="1" colspan="1">35/65</td></tr><tr><td align="left" rowspan="1" colspan="1">Race (%) (CA/AA/Asian)</td><td align="center" rowspan="1" colspan="1">80/20/0</td><td align="center" rowspan="1" colspan="1">75/25/0</td><td align="center" rowspan="1" colspan="1">75/15/10</td><td align="center" rowspan="1" colspan="1">50/50/0</td></tr><tr><td align="left" rowspan="1" colspan="1">Smokers (%)</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Concomitant disease (%)<sup>a</sup>
</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol medication use (%)<sup>b</sup>
</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">Framingham 10-year risk (%)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td></tr></tbody></table><table-wrap-foot><fn><p> 
<sup>a</sup>includes hypertension (overall incidence: 55%), diabetes (5%), atherosclerotic cardiovascular disease (1%), or restrictive/obstructive airway disease (8%).</p></fn><fn><p> 
<sup>b</sup>&gt;75% of the cholesterol medication used in any group were statins.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Self-reported adverse drug reactions (ADRs)<sup>a</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">ADRs reported (%)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value <break></break>(versus placebo)</th><th align="center" rowspan="1" colspan="1">Type of ADR (#)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any pterostilbene</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">10 (16.7)</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">High-dose pterostilbene</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">5 (25)</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">Gastrointestinal (2)<break></break>Increased appetite (2)<break></break>Itching (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-dose pterostilbene</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">3 (15)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">Muscle pain (2)<break></break>Increased appetite (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-dose + grape extract</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">2 (10)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">Muscle pain (1)<break></break>Increased appetite (1)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">2 (10)</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">Gastrointestinal (1)<break></break>Itching (1)</td></tr></tbody></table><table-wrap-foot><fn><p> 
<sup>a</sup>Intention-to-treat population evaluated.</p></fn></table-wrap-foot></table-wrap></floats-group></article>